





Mastorakos Lab

Surgical Intervention in ICH Updates

Panagiotis Mastorakos, MD PhD
Assistant Professor of Neurological Surgery, Neurology, Immunology
University of Texas Southwestern
Peter O'Donnell Jr. Brain Institute



UT Southwestern
O'Donnell Brain Institute



Disclosures


- Peter O'Donnell Jr. Brain Institute Sprouts Program
- NREF Research Fellowship Grant / Young Clinician Investigator Award
- Disease-Oriented Clinical Scholars (DOCS) Program

Learning Objectives



- ICH pathophysiology
- Surgical approaches to ICH
- Identify ICH patients most likely to benefit from surgery
- Summarize results/limitations of key randomized trials
- Compare open vs minimally invasive approaches
- Apply a practical selection & timing framework

Background

- ✓ Accounts for **~10% of all strokes**
- ✓ Associated with **high early mortality and morbidity**
- ✓ Limited disease-modifying medical therapies
- ✓ Secondary injury driven by:
 - Mass effect and elevated ICP
 - Perihematomal edema
 - Neuroinflammation and toxicity of blood products
- ✓ Optimal role of surgery remains **controversial and context-dependent**




The pathophysiology of ICH




Innate immune response to ICH: Microglia

Uninjured




0:00
hrs:min

Rosetting
(1-35 min)



0:00
hrs:min

Rosettes
(1h post)




0:00
hrs:min

50 μ m

Cx3Cr1 Evans Blue

Innate immune response to ICH: Monocytes



lectin LysM

“Surgery for ICH” Is Not One Entity

Scenario	Primary Goal	Evidence Base
Salvage surgery (large ICH, herniation)	Survival	Observational
Trial-based evacuation (ENRICH, MISTIE)	Functional outcome	RCTs
Cerebellar ICH	Survival	Observational + consensus
ICH with underlying lesion (AVM, aneurysm, tumor)	Treat underlying cause ± evacuation	Etiology-specific literature

Life-Saving Surgery in ICH: Salvage Indications

Large supratentorial ICH with:

- Herniation physiology
- Refractory intracranial hypertension
- Rapid neurologic deterioration

Goal: **prevent death**, not proven functional recovery

Evidence base:

Observational data + physiologic rationale

No randomized trials

Often involves:

Decompressive craniectomy and/or ICH evacuation



Life-Saving Surgery in ICH: Salvage Indications

Large supratentorial ICH with:

- Herniation physiology
- Refractory intracranial hypertension
- Rapid neurologic deterioration

Goal: **prevent death**, not proven functional recovery


Evidence base:

Observational data + physiologic rationale


No randomized trials

Often involves:

Decompressive craniectomy and/or ICH evacuation



Craniectomy complications could be avoided with MIS



STICH I & STICH II: Open Craniotomy for ICH

Trial	Population / Criteria	Intervention	Primary Outcome	Key Signals / Limitations
STICH I (2005)	Supratentorial ICH ≤72 h Hematoma ≥2 cm GCS ≥5 ~40% lobar, 40% deep Median vol 38 mL	Early surgery (75% craniotomy) ≤24 h vs medical	No difference in favorable GOS at 6 mo OR 0.89 (95% CI 0.66–1.19)	Possible benefit in lobar ICH ≤1 cm from surface 26% crossover to surgery
STICH II (2013)	Lobar ICH only Volume 10–100 mL No IVH GCS-M ≥5, GCS-E ≥2	Early surgery (99% craniotomy) ≤12 h vs medical	No difference in favorable GOS at 6 mo OR 0.86 (95% CI 0.62–1.20)	Surgery did not worsen outcomes Signal toward benefit in poor-prognosis patients

STICH I & STICH II: Open Craniotomy for ICH

- **STICH I (2005)**

- Early surgery vs initial conservative treatment

- Broad supratentorial ICH population

- No overall functional or mortality benefit**

- **STICH II (2013)**

- Selected patients with **superficial lobar ICH** (no IVH)

- Early surgery **did not worsen outcomes**

- Small signal toward survival benefit, no clear functional improvement

- **Key Limitations**

- Delayed timing in many patients

- Large craniotomy with significant tissue disruption

- Heterogeneous patient selection

Why do we still do open crani/evac?

- **What STICH Studied**

- Stable supratentorial ICH
- GCS thresholds suggesting survivability (e.g., GCS ≥ 5)
- Patients **not requiring immediate life-saving decompression**
- Timing allowed for randomization (often hours after ictus)

- **What STICH Did *Not* Study**

- Moribund patients
- Patients with **active herniation requiring emergent evacuation**
- Clear-cut “no-choice” surgical scenarios
- Posterior fossa hemorrhage

Cerebellar ICH: A Clear Surgical Indication

Posterior fossa has **minimal compensatory reserve**

Rapid brainstem compression and hydrocephalus common

Surgery recommended for:

- Neurologic decline

- Brainstem compression

- Obstructive hydrocephalus


- Large hematoma (>3 cm/ >15 cc)

Evidence:

- Observational data + consensus



Guideline-driven













Secondary ICH: Etiology-Directed Surgery


- Surgery/endovascular intervention targets the **underlying pathology**
- Hematoma evacuation is often **adjunctive**
- Excluded from primary ICH evacuation trials
- Fundamentally different from “primary ICH”














*When possible in the hyperacute phase, otherwise perform MR after NCCT+CTA before hospital discharge

When Is DSA Warranted in Intracerebral Hemorrhage?

- **Positive or equivocal CTA**
- **CTA negative but high suspicion for secondary cause**
- Young patient
- Lobar or posterior fossa ICH
- No history of hypertension / no small-vessel disease on CT
- Primary IVH or atypical hemorrhage pattern
- **Spot sign?**
- **If CTA negative**
- Consider **MRI/MRA** or **delayed vascular imaging** once hematoma resolves

Evacuation for Selected Primary ICH





Why Minimally Invasive Surgery (MIS) for ICH?

Rationale

- Conventional craniotomy failed to improve functional outcomes
- Surgical corridor injury may negate clot removal benefit
- MIS aims to:
 - Reduce **mass effect**
 - Minimize **white-matter disruption**
 - Limit secondary injury from blood products

MISTIE III (2019): Catheter-Based Evacuation + Alteplase

Domain	Key Details
Population	ICH ≥ 30 mL Clot stability on repeat CT at 6 h 62% basal ganglia, 38% lobar Median volume 41.8 mL (IQR 30.8–54.5)
Intervention	Alteplase via stereotactic catheter (up to 9 doses, q8h) Target residual clot ≤ 15 mL
Comparator	Medical management
Primary Outcome	No difference in favorable outcome (dichotomized mRS at 12 mo) Absolute risk difference 4% (95% CI -4% to 12%), $p = 0.33$
Key Secondary Findings	\downarrow Mortality with surgery Adjusted HR 0.67 (95% CI 0.45–0.98), $p = 0.037$ Evacuation target mattered: 58% achieved residual clot ≤ 15 mL +10.5% absolute increase in favorable mRS vs medical therapy (95% CI 1.0–20.0), $p = 0.03$

Functional benefit was seen **only when effective clot reduction (≤ 15 mL residual) was achieved**, establishing a dose–response relationship.

ENRICH Trial (2023): Early Minimally Invasive Parafascicular Surgery (MIPS)

Domain	Key Details
Population	ICH 30–80 mL (68% lobar, 32% anterior basal ganglia) GCS 5–14 Mean volume 50.5 mL (± 14.6)
Intervention	MIPS (BrainPath) Median surgery time 16.6 ± 6.3 h Initiation ≤ 24 h (≤ 8 h preferred)
Comparator	Guideline-based medical management
Primary Outcome	Improved posterior distribution of treatment effect Mean utility-weighted mRS: • Overall: 0.913 • Lobar ICH: 0.9968 • Anterior basal ganglia ICH: 0.5301
Key Secondary Findings	Mean end-of-treatment ICH volume 14.9 mL 72.7% achieved residual clot ≤ 15 mL Shorter ICU LOS (7.0 vs 9.6 d, $p < 0.001$) Shorter hospital LOS (14.7 vs 17.1 d, $p = 0.021$) Fewer decompressive craniectomies (3.3% vs 20%, $p < 0.001$)
Mortality	Lower 30-day mortality (9.3% vs 18.1%, $p = 0.027$) No difference in 180-day mortality HR 0.789 (95% CI 0.485–1.285), $p = 0.341$

MISTIE III

Technique: catheter-based aspiration + tPA

No primary functional outcome benefit

Strong volume–outcome relationship

<15 mL residual = better outcomes

It's not enough to operate, you have to
evacuate effectively.

ENRICH Trial

Early, minimally invasive parafascicular surgery

Target: lobar ICH

Improved functional outcomes

Reinforces:

- Early intervention
- Anatomy-based approach

Supporting & Adjunctive Trials in ICH Surgery

Endoscopic & Device-Assisted Evacuation

- Multiple feasibility and safety studies of endoscopic hematoma evacuation
- Demonstrate effective clot removal with reduced surgical exposure
- Functional outcome benefit remains variable and technique-dependent (*e.g., MIND trial*)

Intraventricular Hemorrhage (IVH): Mechanistic Support

- **CLEAR III:** intraventricular thrombolysis did not improve functional outcome overall
- There's still utility in select cases

Practical Decision-Making

Who Should Be Considered for Surgery?

- Lobar ICH
- Moderate size (30–80 mL)
- Clinical deterioration or mass effect
- Younger patients / good baseline function

Who Should NOT

- Deep basal ganglia hemorrhage
- Extensive IVH without hydrocephalus
- Severe comorbidities
- Poor premorbid status

Timing Matters

- Earlier = better
- Before irreversible secondary injury
- Avoid ultra-delayed “salvage” surgery